【热门产品推介】Research Grade Bersanlimab
Bersanlimab (BI-505) 是一种全人源单克隆抗体，靶向细胞间粘附分子-1 (ICAM-1 或 CD54)。Bersanlimab 具有抗癌作用
武汉佰乐博代理：Research Grade Bersanlimab
货号：DHC16001
产品链接：http://www.atagenix.com/product_detail-75477.html
产品购买联系方式：027-65279366
产品介绍：Bersanlimab (BI-505) 是一种全人源单克隆抗体，靶向细胞间粘附分子-1 (ICAM-1 或 CD54)。Bersanlimab 具有抗癌作用。
通用名:Bersanlimab
纯度:>95% by SDS-PAGE.
浓度:1mg/ml
Formulationicon:0.01M PBS, pH 7.4.
内毒素:Please contact with the lab for this information.
别名:BI-505
靶点;物种:Human CD54/ICAM1
种类；Homo sapiens
受体鉴定：IgG1-lambda
CAS: 1987854-08-9
存储条件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
参考文献：
Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. PMID: 27136449
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature. PMID: 27532314
Self-management interventions for people with chronic obstructive pulmonary disease. PMID: 35001366
Efficacy and safety of core stability training on gait of children with cerebral palsy: A protocol for a systematic review and meta-analysis. PMID: 31914039
What is "quality of evidence" and why is it important to clinicians? PMID: 18456631
Socioeconomic status and health: what we know and what we don't. PMID: 10681884
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. PMID: 18483053
Acupuncture for heart failure: a Bayesian network systematic review and meta-analysis protocol. PMID: 34763474
研究应用：CD38是一个经过充分验证的治疗多发性骨髓瘤的靶点。虽然抗cd38单克隆抗体治疗使多发性骨髓瘤患者获得了显著的缓解，但仍有相当一部分患者未能缓解，几乎所有患者最终均复发。部分耐药机制与CD38表达下调有关。此外，CD38广泛表达于正常的淋巴细胞、髓细胞以及红细胞(rbc)。为了有效地靶向肿瘤细胞上的CD38，我们假设针对肿瘤相关引导抗原(TAG)和CD38的双特异性抗体可以实现肿瘤特异性并提高效力。ICAM-1是一种免疫球蛋白样细胞黏附分子，在多发性骨髓瘤、淋巴瘤和部分实体瘤中高表达。抗ICAM-1抗体bersanlimab (BI505, BioInvent)耐受性良好，但对MM患者的临床疗效有限。我们制备了不同格式和几何形状的双特异性CD38 x ICAM-1抗体，并比较了它们对CD38低表达和中表达icam1高的肿瘤细胞的体外活性。我们的研究结果表明，非对称1+1格式对ICAM-1CD38+培养基或ICAM-1CD38+低表达细胞均具有较强的ADCC和ADCP活性。Fc修饰进一步提高了双特异性抗体的ADCC活性。为了进一步了解抗原密度的影响，我们测试了ADCC活性在一系列表达CD38和ICAM-1的骨髓瘤和淋巴瘤细胞系上的选择。我们观察到在CD38表达极低的细胞上有较好的ADCC活性。此外，我们发现，与双价CD38抗体相比，双特异性抗体减少了NK细胞的杀兄弟作用和红细胞结合。最重要的是，CD38 x ICAM1双特异性抗体在体内骨髓瘤和淋巴瘤模型中显示出有效的肿瘤抑制活性。这些研究提示CD38 x ICAM-1双特异性抗体对淋巴瘤和多发性骨髓瘤有多种作用方式。
